<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Neuroscience Physiology and Pharmacology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/95402A11-0224-47AF-8EC0-5E2E5BF51F67"><gtr:id>95402A11-0224-47AF-8EC0-5E2E5BF51F67</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Brown</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9408C098-D406-49FD-AB23-F608AF7EC776"><gtr:id>9408C098-D406-49FD-AB23-F608AF7EC776</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:otherNames>Henry</gtr:otherNames><gtr:surname>Dickenson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0500194"><gtr:id>709F0F4F-7437-4ED7-BF93-7FC21CE1CBCA</gtr:id><gtr:title>Kv7/KCNQ(M) potassium channels and nociception</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500194</gtr:grantReference><gtr:abstractText>Potassium channels are proteins that span the outer membrane of nerve cells. The pores open when the nerve cells are active, and allow charged potassium ions to move from inside the nerve cell to the outside. As a result, the nerve cell membrane becomes hyperpolarized and the activity of the cell is reduced. The Kv7 family of potassium channels is interesting because members of this family play an important role in regulating nerve cell activity, and also because mutations in their genes cause certain genetic diseases. In some previous work, we showed that these (Kv7) channels are present in the sensory neurons that conduct pain impulses to the central nervous system (cns), and that a drug called retigabine, which increases the activity of these channels, reduced the transmission of some forms of painful stimuli in the first pain-receiving station in the spinal cord and reduced the behavioural responses of rats to the pain associated with chronic inflammation. We now wish to find out more about the role of these potassium channels in regulating the generation and transmission of painful stimuli, and more precisely how increasing their activity reduces chronic pain. We will do this by recording the electrical discharges in sensory pain fibres from the skin and the transmission of sensory ?painful? (nociceptive) impulses in the spinal cord. We will also test what happens to the perception and transmission of painful stimuli in mice in which one copy of the gene encoding one of the Kv7 proteins has been deleted. (We have a colony of such mice.) We then want to find out to whether substances that cause pain when released from damaged cells exert some of their effect by inhibiting these channels, and whether nerve injury alters the number and distribution of these channels. Although many drugs can reduce pain, they are generally not so effective in chronic inflammatory pain (e.g., in cancer or arthritis) or neuropathic pain (i.e., due to nerve injury), whereas retigabine seems unusually effective in animal models of such forms of pain. We hope our work will show why this is so, and perhaps help toward the development of better drugs for treating chronic and neuropathic pain states. We will not be trying to develop drugs ourselves, but shall be interacting with a pharmaceutical company via a separate EU Consortium, and with the wider biomedical community through the London Pain Consortium and other avenues.</gtr:abstractText><gtr:technicalSummary>Kv7 (KCNQ) channels are a family of 5 K+ channel subunits, 4 of which are expressed in the nervous system. There they form subunits of a native channel originally termed the ?M channel?, which regulates neuronal excitability. M channels are closed by neurotransmitters acting on Gq-coupled receptors, resulting in increased neuronal excitability. The physiological and medical importance of Kv7 channels is indicated by the fact that mutations in 4 of their 5 human genes result in inherited diseases. In recent experiments we found that Kv7 channels and their functional M current counterparts are strongly expressed in nociceptive sensory neurons. Increasing their activity with the Kv7 channel enhancer retigabine reduced some forms of nociceptive transmission in the dorsal horn of the spinal cord in a manner not replicated by conventional analgesics and reduced behavioural responses in an animal model of neuropathic pain (the latter also confirmed by others). This suggests a novel target for the pharmacotherapy of intractable inflammatory and neuropathic pain. To develop this, it is essential to understand the role of Kv7 channels in the transmission of normal and neuropathic pain. We therefore propose to address the following questions: (1). Are the retigabine-sensitive channels located at the peripheral or central ends of the sensory neuraxis, or both? (2).What is the normal role of these channels in pain transmission? (3) To what extent can the effects of chemical mediators of pain, such as ATP and peptides, be attributed to regulation of Kv7 channels? (4) Are there adaptive changes in Kv7 channel expression or function during neuropathic pain induced by nerve injury that might be relevant to the use of Kv7-enhancing drugs? We propose to answer these questions using a combination of (a) electrophysiological recording of peripheral (skin-nerve) and central (dorsal horn) transmission, and of membrane currents in dissociated nociceptive sensory neurons, and (b) PCR and immunocytochemical assessment of Kv7 expression in sensory neurons and dorsal spinal cord, supplemented where appropriate by (c) behavioural monitoring of various forms of nociceptive stimulation. The role of Kv7 channels in nociceptive responses will be tested using pharmacological and genetic suppression of Kv7 function (the latter using genetically-modified mice deficient in Kv7 subunit expression). The results should increase knowledge of Kv7 channel function, and of the regulation of nociceptive transmission, and might assist in the development and application of new therapies for intractable inflammatory and neuropathic pain.</gtr:technicalSummary><gtr:fund><gtr:end>2008-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>480351</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Contributed to direction of research into therapy of pain in the pharmaceutical industry</gtr:description><gtr:id>E23B42D6-BB56-4C79-9691-31087459F6B1</gtr:id><gtr:impact>Contribution to research directions at Pfizer UK.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Pain research</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/18C4B7D6-F1ED-41B5-80E4-5435804C654D"><gtr:id>18C4B7D6-F1ED-41B5-80E4-5435804C654D</gtr:id><gtr:title>Regulation of M(Kv7.2/7.3) channels in neurons by PIP(2) and products of PIP(2) hydrolysis: significance for receptor-mediated inhibition.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/11fc9934b0efa7529e02c1dc292efc75"><gtr:id>11fc9934b0efa7529e02c1dc292efc75</gtr:id><gtr:otherNames>Brown DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E010B3DE-63A6-4527-9743-DEFD5F069BB5"><gtr:id>E010B3DE-63A6-4527-9743-DEFD5F069BB5</gtr:id><gtr:title>Kv7/M-type potassium channels in rat skin keratinocytes.</gtr:title><gtr:parentPublicationTitle>Pflugers Archiv : European journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1aa4b0a2228ad71983839d6894e52f1f"><gtr:id>1aa4b0a2228ad71983839d6894e52f1f</gtr:id><gtr:otherNames>Reilly JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0031-6768</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9C752A47-EB13-4E56-9AD8-FE2CCC65F1FE"><gtr:id>9C752A47-EB13-4E56-9AD8-FE2CCC65F1FE</gtr:id><gtr:title>Effects of KCNQ2 gene truncation on M-type Kv7 potassium currents.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8fd10fb9fdd2fc2f43976d33c0d0feab"><gtr:id>8fd10fb9fdd2fc2f43976d33c0d0feab</gtr:id><gtr:otherNames>Robbins J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/749DFD06-CBAC-41E0-9895-C927DA7E3479"><gtr:id>749DFD06-CBAC-41E0-9895-C927DA7E3479</gtr:id><gtr:title>Some new insights into the molecular mechanisms of pain perception.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/11fc9934b0efa7529e02c1dc292efc75"><gtr:id>11fc9934b0efa7529e02c1dc292efc75</gtr:id><gtr:otherNames>Brown DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C317A888-C63C-4BFC-BFF1-13CD93D6C408"><gtr:id>C317A888-C63C-4BFC-BFF1-13CD93D6C408</gtr:id><gtr:title>Muscarinic acetylcholine receptors (mAChRs) in the nervous system: some functions and mechanisms.</gtr:title><gtr:parentPublicationTitle>Journal of molecular neuroscience : MN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/11fc9934b0efa7529e02c1dc292efc75"><gtr:id>11fc9934b0efa7529e02c1dc292efc75</gtr:id><gtr:otherNames>Brown DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0895-8696</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7F674E81-AEDC-4DF3-857C-661F2D5F2FB4"><gtr:id>7F674E81-AEDC-4DF3-857C-661F2D5F2FB4</gtr:id><gtr:title>Functional significance of M-type potassium channels in nociceptive cutaneous sensory endings.</gtr:title><gtr:parentPublicationTitle>Frontiers in molecular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d2969d61ef20c7d086df9105c067c595"><gtr:id>d2969d61ef20c7d086df9105c067c595</gtr:id><gtr:otherNames>Passmore GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1662-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D3D6428E-C472-49D2-A8F2-D7E72712F685"><gtr:id>D3D6428E-C472-49D2-A8F2-D7E72712F685</gtr:id><gtr:title>Kv7 (KCNQ) potassium channels that are mutated in human diseases.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/11fc9934b0efa7529e02c1dc292efc75"><gtr:id>11fc9934b0efa7529e02c1dc292efc75</gtr:id><gtr:otherNames>Brown DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2FEE95F4-B610-481A-B25D-5AB7CFAE0C65"><gtr:id>2FEE95F4-B610-481A-B25D-5AB7CFAE0C65</gtr:id><gtr:title>Retigabine reduces the excitability of unmyelinated peripheral human axons.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/569ade516eb5af3049d49ee95ba412cd"><gtr:id>569ade516eb5af3049d49ee95ba412cd</gtr:id><gtr:otherNames>Lang PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4043E943-4A72-4276-9F80-A461ED897BB2"><gtr:id>4043E943-4A72-4276-9F80-A461ED897BB2</gtr:id><gtr:title>Neural KCNQ (Kv7) channels.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/11fc9934b0efa7529e02c1dc292efc75"><gtr:id>11fc9934b0efa7529e02c1dc292efc75</gtr:id><gtr:otherNames>Brown DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5DFC2691-D0FD-4E68-B2E8-F21203097B7D"><gtr:id>5DFC2691-D0FD-4E68-B2E8-F21203097B7D</gtr:id><gtr:title>Presynaptic signaling by heterotrimeric G-proteins.</gtr:title><gtr:parentPublicationTitle>Handbook of experimental pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/11fc9934b0efa7529e02c1dc292efc75"><gtr:id>11fc9934b0efa7529e02c1dc292efc75</gtr:id><gtr:otherNames>Brown DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0171-2004</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500194</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>